Implantica (IMP) Q3 2024 earnings summary

Executive summary

• Q3 2024 net sales reached €344,000, up 41% year-over-year, driven by RefluxStop™ adoption among European key opinion leaders.

• Over 1,000 RefluxStop™ surgeries performed in Europe, with strong clinical outcomes and growing surgeon interest.

• U.S. and Japan market entry preparations underway, with significant interest from leading centers and surgeons.

• Cash position at €69.3 million as of September 30, 2024, with no interest-bearing debt and a 96.2% equity ratio.

• Operating loss for Q3 was €5.3 million, a 7% decrease year-over-year, but nine-month operating loss widened to €18.3 million due to FDA submission costs.

Financial highlights

• Q3 2024 net sales: €344,000, up from €244,000 in Q3 2023; nine-month net sales: €1.5 million, up 66%.

• Q3 adjusted gross margin improved to 97% (from 94%); nine-month margin at 93%.

• Q3 operating loss: €5.3 million, down 7% year-over-year; nine-month operating loss: €18.3 million.

• Net cash outflow from operations was €4.8 million in Q3 and €17.8 million for the nine months.

• Basic and diluted loss per Class A share was €0.09 in Q3 and €0.23 for the nine months.

Outlook and guidance

• Focus on expanding reimbursement and market access in Europe and preparing for US and Japan market entry.

• U.S. FDA PMA process ongoing, with module three submission expected in approximately three months.

• Randomized controlled trial comparing RefluxStop™ to Nissen fundoplication enrolling 200 patients, with first results expected within 1–1.5 years after enrollment.

• Anticipates substantial US commercial footprint within 1–2 years post-FDA approval.

• Selective sales strategy targeting key opinion leaders in Europe.